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ABSTRACT 
The chemotherap~ pro~ram of the l\ational Cancer Institute functions m a major part as 
a dru~ de"elopm~nt program The program screen!' lar~re numhel'!-. uf compounds each year 
m a predommately rn lito screen utilizmg mou!'.e leukem1a Ll210 as tts most Important 
component. Input to the ht'reen comes from the synthehl!> of cogener!'. of known active 
chemicalg (rat ion a! base) and from heterogeneous rlas!;es of chemicals, uncharacterized an-
Uhiottcs and plant products (empirical base). The determination of clinical activity and its 
t•orrelation with the expenmental screen depends significantly on an act•epted definition of 
an adequate trial The clinical trial of new drugs is divided into three phases and the 
chemotherapy pro~ram defines an adequate trial as the establishment of a maximally toler-
ated do!>e (phase I) and the evaluation on an adequate dosage schedule in at least six "sig-
nal' tumor tvpes (phase[() 
As a m1mmum 1t would be unfair to label a drug as "mactt,e" until it has been ade-
quately evaluated m at least 10- 15 evaluable patients m the six signal tumor types(iun~. 
breast, colon. acute lymphocytic and acute myelocytic leukemia and lymphosarcoma) and 
found to have msuffic1t>nt clinical activity mall of them. 
Definin~ an adequate trial has to take into account the question of whether an adequate 
dosage schedule was used The chemotherapy program has a defined protocol for schedule 
dependenc~ test in~ of all of its drugs in t>).penmental syhtems and m this way attempts to 
define which schedule might be optimal for usa~e m men. The posttJve cnrrelauon for such 
an appmach has b~.>t.>n shown w1th drugs such as methotrexate and arabinosyl cytosme. 
The C'hemntherapy Pro~ram of the :-;ational 
Cancer Institute functwns in part as a drug de-
"elopment program. The objectives of the pro-
gram are shown in Fi~re 1 (1 ). 
A Cancer Chemotherapy Program, like any 
other dru~ development effort IS dependent upon 
equally important contributions by the chemist. 
expenmental chemotherapist and pharmacologist. 
and the research rltnic1an. whu m close collabora-
tion mu!>t provide large numbers of potentially 
useful mater111ls. evaluate them agamst mean-
ingful pre-clinical systems. select the most prom-
l!;tng and finally evaluate these agamst the target 
human disease(s) . 
The two major appmache,.. to providing new 
drugs for pre-clintcal e\'aluation with the view to 
clinical tnal are ( 1l synthesis of cogeners of 
known "act 1\ e" chemtcals using structure-ac-
tivity relatton~hip data and fundamental bio-
chemical knowledge as a ~ide and (2) broad 
screenmg of heterogeneous classes of chemicals. 
uncharacterized antibiotics and plant products in 
search of completely new classes of active drug~ 
with mechanisms nf aetion different from the 
known tumor mhibtting agents. It is to the latter 
aspect nf broad screenin~ that I would like to 
address my~elf. 
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Fi~re 2 illustrates the concept of a screen. A 
screen attempts to keep out the bulk of the nega-
tive materials and concentrate for further study 
those matenals that have the greatest promise. It 
cannot be designed to yield every compound that 
will show act1vity clinically without almost surely 
includmg an unbearable number of false posi-
ti\ es. and it cannot be designed to eliminate 
every compound that IS not active without losing 
some of the acuvities. 
Fi~re .1 uutlines the historical de,·elopmem of 
the Chemotherap) Prugram screen . Initially. 
three tumor systems were uttltzed : leukemia 
L 1210, because of sug~esll\'e ev1dence that it had 
some predictive \'Slue m the clinic (2) and sar-
coma 180 and carcmoma 755. because of a) their 
cytolo~ical and pathological resemblances to 
major human maltgnancies and bl the feasibility 
of quickly generatm~ the mice required. Random-
bred mice could be used for Sl80 and BDF 1 hy-
hrids could be used for both Ll210 and Ca-755 (1) . 
Following an initial experience with these three 
model systems, it was considered desirable to 
extend the screenmg to additional systems on the 
grounds that the initial three screening systems 
might be too lim1ted m their selection capacity 
and thereby neglect to 1dentifs many compounds 
of potenttal value lor the clinic. In order to gain a 
broad experience, the ~creenmg was extended to a 
w1de ran~e of systems With L 1210 as the only 
system in which every compound was tested. 
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ObJectwes of the chemotherapy program Natrona/ 
Cancer Institute 
1. Procurement, preparation. and synthesa~ of chemicnl 
agents and fermentation and plant products. 
2. Evaluation of these agents in experimental systems 
for anti-cancer activity and recommendation of new 
agents for cltnacal trial. 
3. Study of toxicologic and pharmacologic effects of 
new agents in animals to permit their study m man 
with the greatest degree of safety and effectiveness. 
4. Development of new and improved laboratory 
methods for evaluating antitumor agents. 
5. Study of drug action. 
6. Fundamental studies to develop new approaches to 
improved chemotherapy in man. 
7. Evaluation of new agents in man. 
Fac. 1 
WHAT IS A SCREEN? 
• 
8o CLINICALLY ACTIVE C> o • 0 
0 ~ \• C LINICALLY INACTIVE 
Frc. 2 
Hrstoncal development of chemotherapy program 
.ycreen 
1955 Sarcoma 180, Carcinoma 755, Leukem ia 
Ll210 
1960 Leukemia Ll2JO pluh 2 additional sys-
tems out of a pool of 20 
1965 Leukemia Ll210, Walker carcinosarcoma 
2fl6 
1968 Leukemia L1 210, Leukemaa P -388 for 
naturnl products only 
1971 72 Leukemia L1210 and P-388 plus either B-
16 melanoma or Lewis lung tumor 
Frc. 3 
In 1965, retrospective analysis by Goldin, Ven -
ditti and others of the mass ive data that had ac-
cumulated over the years led to a discontinuance 
of the broad s pectrum screen in fa\'Or of the utili -
zation of the L1210 and Walker 256 screening 
system. Recently we have shelved the Walker 
screen pending the acquisition of clinical experi-
ence with a number of compounds active in this 
system. so that primary emphas is rs now placed 
on the leuke mia L1 210 system for the identifica-
tion of new compounds. The leukemia P-388 
system is also used for all natural products a'! it 
has better sens ith·i ty for c rude fraction!>. 
lt is recognized , however, that the Ll 210 
system has its own limitations especially when 
used as the only screen, and the program is cur-
rently deciding on a second tumor system which, 
hopefully, will have greater predictability for 
drugs with acti,·ity against solid tumors. We are 
at present giving very close scrutiny to the Lewis 
lung tumor and the B- 16 melanoma in this re-
gard. 
Figure 4 outlines the broad ~chema of our pre-
clinical screening and drug evaluation. For initial 
tes ting we will use the KB cell culture system 
when we have only a tiny amount of drug. or 
where we want to check on activity during mul-
tiple processing steps. With adequate drug, we do 
a dose response test in leukemia Ll210 and tebt 
on a single dose, day 2 schedule, as well as a daily 
"' 5 schedule. We demand a 50% increase in life 
span before we consider a drug fo r fu rther testing. 
If this degree of activity is observed we repeat the 
tes t for confirmation. ideally using another con-
tracting laboratory. 
When Jnitial activity is confirmed. the drug is 
brought to the chemotherapy s taff where a final 
decision is made as to whether this drug should 
be developed lor clinical trial. This decision is 
based on the uniqueness of the struc ture as well 
as the experimental activity. This is done in con-
formance with a linear array decision network 
apparatus which the program has developed to 
st reamline the movement of dntgb to clinical 
trial. 
When a drug has passed this primary screen ing 
phase it then enters secondary evaluation, which 
includes schedule dependency studies, determina-
tion of optimal route of administration, t esting 
Schema of preclinrcal .~creenrng and drug evaluation 
I. Primary Screen 
A. Initial testing 
I. In t•ltra-KB cell culture 
:2. In uiua-1.1210 
B Activity confirmation 
II. econdary E"aluation 
A. Schedule dependency studies 
B. Determination of optimal route of administrntion 
C. Testing against intracrnnial implanted disease 
D. Vehicle t esting 
E Testmg in other system, 
E-6. B-16 melanoma. Lewas lung, t>pontanenUh 
AKR 
Ftc. ~ 
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lor al'tl\' lty against tumor cells 111 pharmacologic 
sanctuaries such as the central ner ... ous system. 
vehicle testing and t estmg m other systems. 
Once it has been demonstrated rhal it is po!>-
sihle to create model systems for screening and 
evaluation of a quantitative nature, usually taking 
into account ' ' arious aspects of the host -tumor-
drug mterrelationship, the quest ion presents itselt 
a..., to whether the systems are rele,•anc ro the 
clinir Do the model test »Y~tems selected for use 
idenuty compounds with ~ high likelihood of ac-
tivity 111 the clinic? Obviouf;ly, if the predicta-
bility value of the system is nil. the screening 
evaluation effort becomes irrelevant to the clinic. 
In developing a mass screening program there 
i" the practical prohlem of developing a system 
which. besides being predicrr,·e, is reproducible in 
its results and at the same time economically fea-
sible. \\'e have felt that the leukemia L1210 meets 
these specifications better than any other system 
with which we ha\e had experience. 
In leukemia Ll210 there i!\ an approximately 
two day lag phase aS$ociated with transplanta-
tion. This period is followed by a period of lag 
phase proliferation (gene rat ron time. 0.55 days) 
whiC'h continues until host death. at which lime 
the host's leukemic populatwn rs of the order of 
one brllron cells. Screemng rn Ll210 which beg-ms 
on day 2 is carried out under conditions far re-
moved from the w;ual clinical situauon in acute 
Jeukemta ; I.e ., in l'WO treatment Of' animals 
bE'aring relatively small numbers of leukemic 
cells. Still, the wurth of a !i<:reen hru; to be deter-
mined 111 the end by the clinical results obtained. 
Any type of mass screening involves compro-
mise and chemotherapy screenmg is no except ion. 
II has to he accepted that , of the materials that 
get through anv screen , a certain percentage will 
be inacti\'e clinrcally and. unfortunately, the 
screen will miss active materials. The best screen 
i!i oh\'iously one that misses the fewest active 
materials and that select~ the fewest inactive 
ones. 
In any screen there are four possibilities and 
these are outlined in Figure :J. Ln order tu fully 
evaluate a screen the data on all four possibilities 
has to bt> pvaluated. Thts is rarely possible. how-
e\er. a;; rt 1!:> not feasible to test all your negatives 
in the screen clinically in order to find out how 
many are true negatives and how many are falsP 
ne~tatrves. Therefore, the chemotherapy screen 
Possible re.~ult .~ U'lth am .~creening system 
--True t><ISIII\~--1 
F'al~e pClsil ive 
True negauve 
False nc~tat ive 
Frl: fi 
_j 
can only be judged on lt!o posH ivl'!> and what hap-
pens Lo 1 hem in thP clinic 
The determination of rlinical activity and it;; 
correlation with the experimental screen depends 
significantly on an accepted definition of an nde-
quate trial. Drug~ selected hy a highly quantira-
tive system such o~ leukemra Ll210 ma) only 
tentali\ely be classified as fal»e positives if. be -
cause of poor ab:-orption. systemic inacti,·ation. or 
limiting toxicitJ; for the mndalll) ol therap~ em 
ployed. etc., they have not rPceived an adequate 
triaL As a minimum an adequate trial requires 
that a drug be administered in the range of the 
maximum tolerated do!'e and on an adequate 
dosage schedule. 
The Chemotherapy Program ha:o evoked the 
climcal evaluation of a ne\\ agent into three 
phases which are specifiC modifications of the 
phases requrred by the F'nod and Drug Adminrs 
trat ion. These are outlined below: 
Outlme of Cltnical EvaluatiOn of Neu• Drugs 
Det•eloped by the Natwnal Cancer Institute 
Phase 1-Ciinical Pharmacology 
Advanced cancer patient:. with or wn hout meas-
urable disease 
I. Establish maxrmally tolerated dose 
2. Establish parameters of toxicit) 
:J. Pharmacologic e\'aluation 
4 Antitumor acrrvrty not required 
Phase U-Survey for Clinical Artivity in Patrents 
with Measurable ur evaluable disease 
Non-randnmrzed studies 
2. 10 to 20 patients in 6 "Sl!nlal'' tumors 
a. Adenocarcinoma of colon 
h. Hrunchol{enic carcinoma 
c. Adenocarcinoma of breast 
d . Undiflerentiated lymphosar<·oma 
e. Acute myel11cytic leukemia 
I Acute lymphoc~t1c leukemia 
1 
Pha:.e III-Definiuve Studies w Es tablish Role in 
Cancer Therapy Armamentarium 
Contmlled clinical trials 
2. Cumhrnallon st udres 
l 
Commercral availability 
Phru;e I is limited to clinrcal pharmacology 
The patients utilized have advanced neoplastic 
disease refraciorv to all :otandard therapy for their 
disease. Their estimated survival should be at 
least two months. Mea!:>urable or evaluable dis-
ease is not required. The accomplishment of clin-
i<'al response, all hou~h must Mieworthy when it 
occurs, ts not essentialw evaluarion at this stage 
The aim is io establi~h the maximaJiv tolerated 
dose at the scht>dule used and to esi.ablisb the 
parametel'b ol' tnxicit.v. If a loleraled dose can be 
achieved with toxicity that is predictable, treat-
able and revernible. then Phase II trials are begun. 
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Fu;, 6 Cnntinued 
Pha::.e II l nal con:nsts of a survey for eli meal 
activity agamst a panel ol s1x signal tumor types 
This surve) 1s des1gned w thoroughly test lor 
drug acti\IIV against tumors which are kineticall~ 
described as "fast growing" (leukemia, lym 
phomal and "slow growing" (colon. breast. lung) . 
These studies are usually non-randomized and 
require patients who are clearly e,·aluable as to 
response. meaning m most cases measurable indi-
cator lesions. For each signal lllmor type the 
objectrve respom;e rate 1s looked at in at least 15 
~0 e"aluable pat ients. 
Adenocarcmoma of the hrt>ast and colon and 
bronchogemc carcmoma are used to screen 
against the slow growmg tumors whrch are the 
most resistant to chemotherapeutiC attack. The 
acute leu.kemiru. and lymphoma ha\ e been chosen 
to !->Creen agamst the rapidly growmg and more 
chemotherapeutically sensiti\e tumor types. It is 
felt that thtl' kind of di><ea!!e oriented phase II 
trial is ~upl'rior to the often u~ed general phase II 
trial in whil·h a wide range of tumor types arc 
treated. but only a few of these types m a number 
large enough to gi\'e meanmgful results. It is not 
uncommon rn the older literature to see a drug 
described a~ inact1ve bo~ed on a low percent of 
response in 50 or so patients. a nd to see that onh 
2 or 3 patienb wtth colon or breast cancer were 
treated . 
In add it wn, other 1m portant pa rameters o t 
drug action are e'aluated. II the agent is a new 
chemical structure greater interest is shown . Cur 
rently. a higher pnorit~ 1~ gwen to agents whrch 
are cell-cyrlt' insen~itl\·e and ha'e demonstrated 
the abilit:. to kill nonproliferating cells. Greater 
emphasis is placed on drugs which can attack 
cells in pharmacologic sanctuaries such as the 
central nervous svstem. Suatabiltty for comhma 
t ion chemotherapy. e.g., lack of bone marrow tm. 
icity, alsu upgrades rnterest in moving a drug 
fi1rward in dinical trial. 
If a<·ceptuble actidtv based partially on the 
abO\ e charat·teristics it-i demonstrated in an~ nf 
these s1gnal tumors. then Phase III trial is begun. 
wh1ch is a delinit1'e study to establ1sh the role nf 
the drug in the clinical oncologist's armamen-
tanum. Otscussion of these later tnals ts outside 
tht> scope ol this discussion. 
I mplic1t 111 tht' w.age of the six signal tumor 
types ts a mimmal definrt um of what ronstitutl's 
an adequatl:' clinical evaluation of a new anti 
tumor agent. As a mm1mum. it would be unfatr to 
Protowl for imttalschedule and route dependenc~ 
studies 01101nst L/21()([[')• 
Hnutt' Trtalmtn• !\u. nn To1o.~l nu ol-
<14\0 , ...... h da_y lr~Atmt·nt~t 
IP 1-fl 5 
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' EC'<perimcnts n•nduc1ed in parallel ~roup~ ol lt•u· 
kemtc and normal mice 
label a dmg as " inactl\e" unttl it has be£-n ade-
quately evaluated an at least 10- 15 e\aluable pa 
tientl\ in th£' l"ix signal tumor types. and found to 
have insuff1dent cltmcal acti' ity rn all of them . 
In line with this reasoning, the Cancer Therap~ 
Evaluatwn Bran('h has im;tituted a n intensive 
review nf all cancer chemotherapeutic agents to 
see how mall\ have been adequate!~ e\'aluated h~ 
these standards. a nd to prO\·ide a h1storica l bark· 
ground for the data rap1dly de"elopm!( on the ne'' 
ill\esti~ationol agents. Figure 6 is an outline of 
the data U\'ailahlt' nn the clrnical antitumor ac-
tiVIty on the commonly used commercialh a,·ail-
able agents in the siX signal tumor tvpes and ma-
lignant melanoma, which is a tumor or h igh in-
terest to our program The data is given 1n per 
tent ohjet'll\'e respo nse rate wtth the at·tual 
number of responses per total number of pat1ents 
in parenthe~cs. 
It is clear from thi~ data that most of these 
drug~ have not been fully tested against all seven 
of thc::.e tumtlrs. This dnta also reo,.eals how ten 
uous a practice 11 1s to lt~t false positives fo r nny 
partitular preclinical screen for antitumor agents. 
Data such ns the abo"e does not e,·en bE.'~in to 
take into IH'Cnunt th£' question of whether an ade 
quate dosage schedule was used. An optimal ther 
apeuti( st·hedu(e IS (I renect iOil Of il quiety nf fac -
LOTS. In additiOn to relatl\·e ~ensitlvnv of a Kiven 
neoplasuc cell a;; opposed to the normal celb ol 
the body, there is the problem of the optimal 
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body fluid concentrot ion of drug with time. Ont> 
cannut -.peak cnnf1dently about the reloti,·e "'l'n~i · 
ttnty 111 drugs of \Briou" tumors in \'Oriou::. hn~b 
w tthout hann~: quantitat in• data on the IJII)od 
cuncentrntton" of drug wuh t 1me achieved m the 
comparottve therapeutic trials and the degree of 
advancement and prolifernuve states of the re-
~:>pecuve tumor cell population~ \Vhile thit> can he 
obtamt>d readily in experimental ~'Y~>t(>m. .... buch as 
10 ammals w1th leukemta Ll210, 1t is rar(>l\, if 
ever, obtained in chnical tnul!> · 
One of lhe major factof"' in the steady impruve 
ment in the cont rot of rnpidly gmwmg canc(>r htb 
been the development or more (>ffecttve there· 
peullt: ... chedules than were conce1ved in the (>arty 
days of cancer chemotherapy . It has been f>hnwn 
repeatedly that optimal sch(>dules t·an make the 
difference between a gtHid re ... pnnse nr a poor re· 
sponsl' ur CH'II ... uccess and toilure A.., Sk1pper 
has pointed out ('II. thi~ l·an ur.ly mean that up· 
umal regulot ion ul the drug cunct•nt rnt ion (with 
time) to whil'h both neuplru.tk and nurmnl cell 
populution~ ure exposed ~ignifil·antl~ affects "se-
lectivlt~ ... Al ... o. 11 ~~ clear that opt imul sl'hedulcs 
for different typb of t:hemutheraJ)('Ullc agents 
\ '81')' depenchng un the1r rnechnni"m ul actum 
Al- md1cuted 1n an enrlier prt•sentatiun. the 
Chemothernp) Program ho., a pmtm·ul for tnlttal 
... chedule ond oral route depend('ncy ..,tud1e., 
agaim•t Ll:!lO. Th1s i~ uutlinl·d in figure 7 .-\n 
example nf ... uch n l>tudy i -.hm\n li>r a new drug. 
J!U8nawle, tn FiJ!Url! 8 ( 1!. This drug which ach 
ao; an mhih11nr nf th(> enzym(> rihnnucleuude re· 
ducta;.e ,..hows marked ~chedul(> rie1wndenry wtth 
TilE JOURNAL OF INVESTIGATIVE DERMATOLOGY 
.5-1/ydroxypicolmnldt•hyde thw,emrcarba:wnP (NSC-107392) n LJ2}(} 
Trt·otment -d tto.lul• _' 1_1'•-+--1-lp_•_d•~•· I Sun .~ tolal Opt du:_l_ n • .; till 
( Sw.pension) t (Solutmnl t 
Once, Duy I 
Q:Jh: Dav I 
Qd; 01. 9 
Q:!h; 01 . 9 
Qd; Dl . 5. 9 
Q3h; Dl. 5, 9 















'> 128 1/20 16/ 16 300/8 7R 0/ 10 
9ll U/ 10 1!/8 (6001 'le~ 0/10 
175 0/ 10 8/8 150/8 > 230 :!110 
100 0/ 1() 8/8 400 35 0/10 
>240 10/2() 13/ 16 200/8 '> 450 7/10 
101 ()/ I() 8/8 75 88 0/ 10 
( Expts. OR LE :H09, :Jf,021 
• Total dose per 1 reatment cluy. :0.1~:/Kg 
tIn ~aim~ • Tween 80. 
*In saline f batie (pH 9 10) 
L-Leukemtc mice ~-Nnrmal !\1ice. 
f Ex pt. 08-LE-$531 
UEH. CC:--:SC-ll fiO. 
:-.:eg.-II .• S 25r• . Highest non-lethal dose in parenthese.. 
Ftc: 10 
Mechant~ms of action uersu~ hmetic and thPmpeutit· implicatitlfl,, 
\~!'IH ~SUKJ!Ml .. l1t"' ._, t•f ltC l lnn-- l'uK .. thlt r nd pr1xiur l 111h1bl11un 'r •nnc. ta,·llt lnll lmplu-atl<m n·Cltrd ll11!'("'cl"" phao..t" .,~,-. r.nl\' 
(, Ara-C 'lA polymerase 
2. Hydrnxyurea cleotide redUl'tllse 
:1 Guanazole cleotide reclul'tase 






S Phase specifk 
S Phase spedfic 
S Phase specific 
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12. Actmumy'm 0 
ho,,\·lamine (Purines) 
rtwrnidvlate s\·nthetase: 
incorp. into Rl'I:A 
React>. with 01'-iA {and 
other cell cun~tt t uent..~) 
., 
? 
Complexe~o with 0'\A 






S Phase with ~elf limitation? 
Cyl'le phase non>.pectfic but "ith 
selectivity for population~ with 
a high G. F . 
Cyc:le phase nnnspecific 
Cycle phase nonspecific 
Fl<; II 
distinct :supertonty in results obsened when the 
drug 1s gi\'(>O 8 times a day on days 1. 5 and 9 . 
This type of schedule dependenc~ 1s classical for 
agents which specifically inhibit cells in DNA 
livnthesis. Th(> structures ol .J drugs including 
I{Uanazol(> which shO\\ thi» kind of !>chedule de-
pendency are given in F'ii{Ure 9. Cytosine arabi-
nm.ide work:- via inhibit ion of DNA polymerase 
(5) while the other three a ll inhibit ribonucleotide 
reductase (6 ·8). The data for 5-hydroxypl-
colnaldehyde thwsemtcarbazone (:\SC- I07:J921 ts 
shown in Fii{Ure 10 (41 and again shows the supe-
riority of around the clock intermittent schedule. 
As-indicated earlier, 8k1pper has indicated the 
schedule dependency of drugs rna~· depend tn 
part on thetr mecham~m of action. Ftgure 11. 
taken from the ..... nrk !lf Skipper I 1:11 list~ S(lrne 
major drug~ broken down b) their mechanbm of 
action versus their kinetic and therapeutic impli 
cations. These are separated into four categories: 
ll Th(> S -phase specilic drugs which ha,•e just 
been mentioned. 2) 8 -phase with self limitation 
which include the classic antimetabolites such as 
Methotrexate, 6-Mcrcaptopurine and 5-Fluorour-
acil, aJ The cell phase non-specific agent~ Wtth 
selectivity for populations with high growth frac· 
lions including drug~o such as cyclophosphamide. 
BCKU and CCi\C, 4) Cell cycle non-specific 
drugs such a~ Daunomycin and Actinomycin D. 
Figure 12 c:n outlines the schedule dependency 
CELl CO"~;TROLS 
,'\cht•dull' dt•pendrnn 111 tht> L/2/0 8-v;trm frorh dtM'aw bt•{url "crmtdlnl!"l 
f"ur~ .... m anarnah• bt:arm.c 111bt,M.,t tn• l.t.zlO ult• 
h1dlt'1!.t nonit·thal dt.N f••r t-a< h .. rhtd~a1t" (07l"> 111 1.11101 
\J:NU l"oiratblt' rnd proclun lnhlluuon
 
,,., ... ":f. " [-;;>, l c•r inlUfl\':t\1<1n 41 rl I • II , "m•l• d.,.,., [ I• ~~. da\-. ~ t !_ lU 01\ ~ cl.n\. !. f 10 d .. ;,., ~ l f i and U fLI,-. and U 
Ara-C' 0:'\Aionl\'1 0/ 10 111/'!.~1 Ot!ll +- 0/111 0/ 10 
'!. H\'druxyurea 0'\A lonlyt 0/20 12/30 oJ:m 0/ 10 0/ 10 
1 Guana7ull' 0:'\Aiunlyl 0/ 10 7/20 0/ 10 11/ 10 0/ 10 
Pirolmaldehyde, D'\A I only) ~f 11/30' 0/211 [)/2(1 5-0H T.., 
;, l\ll'thntrexilll: D::\A. R:\',\ . l'rcllein ll!f,O 0, 40 0 / 1'!.11 Of.lO 0 /811 
6 lll\lP D;o..;A, R'\A fl/211 O!:.>o 0/RII O/ J() fl/lO 
'i r. F'l l>:\A. R'\ \ 0/ !0 11/30 0/211 11/'20 0 / 10 
8 C'vwxan 0::\A fond 01her.o"1 ·ll t'99 0/10 fl/.10 11/ !0 IIIlO 
9 RC::\l :\3/50 121:10 ( lfl'l 1/20 fi/10 ll/10 
10. ('('\,\ ? :1.">7/42:, 1 GiGO 1111'1 0/111 fi/10 IX/ 10 I to' I 
----
0/tti 0/Hl II. Oaunumnm D'\A (uther.;'!l 
_L 0/ 10 I ll/30 0 / J(J 12. Actiru1m~·cm 0 0'\A (uthers?l ll/lll 11/:lO ll/20 1 ll/ 10 0/211 j__~ 
• Three enur-e' rather than four. 
· Our !(UBI h to kill leukemic cell, ra.~t~r than they are beinl( n·pl:tced tor long enough tfl rl'dun· tht' viable number 
tn ZERO-wuhnut t\er nverdu~mg 1he ho~t 
' Clearlv fin thi~ model hefore the leukem•c rell pupulat ion ht•l·nm~ "cruwded"l optimal ~rhedulintt can make 
the diflerence hetwetm l>UCC~' and failur«: Abo it appl·o~r.; that tht· appn.ach In optimal 'rheriuhnl! is qulle dllterent 
for agent" which are. 
t ll Cyde ~tage !>pet:lh( te It ~-phn~l' spcl'ifit:l 
121 Cycle stage :;pe<"ifk but self linutintt 
t:il Cycll' "tattl.' nnm.pec1f1c 
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Fu; . 11 
Aro-C m ndult AML nltmt' 
~nm 
10 m~tfrn 'Tl by 12 hour mfu~iun 
I 0 mll/m 'T> by 2·1 hour mfusiun 
30 m~:/m /T) by 12 hour infu,iun 
:m m~:/m D by 2·1-hour infusiun 
:10 m~{m 'D hy 1-hour infusiun 
flO ml{/m .. n b\ 1-hnur infusinn 
100 mg/m'/D by 1-huur infu~inn 
:m m~fm'ID by 1-hour infustun 
100 mgf m'ID hy 1-hour infubiun 
Sllll mj!/m ' -1~ -hour infm.ion. re(lt>at in 14 day~ 
I ~~ ~glm' !:..~hour intu. . ion, repeat ~4 clay\" ;:; mj!(m'/1> l(ill'n a.' 15 ml( fm• pu.~h and fill 
m~rfm• -l ·huur infu~ion x -1 repeated in I day, 
lflll-2110 mg{m1/ l!.k 2-1-hour infusinn >< .J ·I'I 
100-200 m~/m' tl!.ke ... eekl~ hy 2-l·hour infu-ion >< 
1- K ""ek.~ 
W 1110 mg/D by l:!U-hour continunu.'- infusion 
flO- lOll mgiT> hy 72-hour cnntinunu~ infusion 
500 mg/m' Q 2 l!.k.~ by :!-hour infusion with l"•Cala -
tinns uf 2!iO mg/ m 1 at each inJel'licm lup 10 :1000 
mg/m'l 
f>t)O ml(fm• Q 2 ... k .. hy 6-hour in tu,ton l!.llh ,.,.cain · 1 
tiun nl 2.')1) mg /m • (up tn Jifoll m~t 1m rl I 
20 3;, m~t/m ' Q:IH • II Q-tD '< 1 courses -
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CELL CONTROLS 13i 
in the early L1210 system for these agents based 
on the ability to ··cure" animab bearing about 106 
L1210 cells. The S-phase specific agents show the 
schedule dependency outlined previously. The 
cell cycle non-specific agents with selectivity for 
high growth fraction populations ;.how optimal 
efficacy when given as a large single dose. The 
other two groups are uniformly unable to "cure" 
Ll210 on any schedule. Figure 13 (3) looks at the 
schedule dependency based on median increase in 
life span o/, for the highest non-lethal dose. Here 
the data for the S-phase with self limitation 
agents hints at :;uperiority for an intermittent 
:::.chedule but not for one involving around the 
clock therapy. 
Methotrexate represents one of the most fasci -
nating examples of the importance of schedule 
dependency. This is an active compound in leu-
kemia Ll210 and its activity in this experimental 
system is noteworthy for its schedule dependency. 
This was first noted bv Goldin and Venditti. who 
demonstrated that admmistration of metho-
trexate every 4 days was superior to daily ad min-
istration of the drug (9) in two situations: against 
··early" Ll210 (one or two days after inoculation) 
and against advanced L1210 leukemia. after other 
agents had been used to markedly reduce the leu -
kemic cell load. On the other hand. they found 
that daily administration of the drug resulted in 
optimal therapeutic effect against "advanced'' 
disease (in which treatment was not started until 
7 or 8 davs after inoculation. at a time when the 
mace had- an enormous leukemic cell load). lt has 
since been amply demonstrated by 8elawry and 
others that intermittent (twice weekly) metho-
trexate is superior to daily methotrexate for re-
mission maintenance in childhood acute lympho-
c-ytic leukemia ( IU. Ill . 
· Methotrexate has been used clinically on a va-
riety of schedules and it is of interelit to look at 
the p<x1led reported results in the literature for 
this drug against the six "signal .. tumors of the 
Chemotherapy Program types broken down hy 
dosage schedule. This is shown in Figure 14 along 
with data for two other tumors-malignant mela-
noma and inoperable head and neck tumors (12). 
The data in Figure 1-t re,·eal that methotrexate 
has not received an adequate trial in any of these 
8 major clinical tumor types on each of the five 
most commonly used dosage schedules for the 
drug. When one takes into further consideration 
the methotrexate schedules utilizing calcium leu-
the Methotrexate l>Chedules utilizing calcium leu-
covorin "rescue". the complexity of the situation 
becomes readily evident. Clearly it would be a 
mistake to call methotrexate ''inacti\e" in breast 
cancer, colon cancer or lung cancer based on the 
available data. One could even advance the a rgu-
ment that on selected schedules. this drug may be 
as active as any single agent officially recom-
mended for these diseases. although obviously 
larger numbers and controlled comparative trials 
would be required before a definitive statement 
could be made. This does, however. again point 
out the hazardousness of labeling drugs as false 
positi,·e for a given screening system. 
Arabinosyl cytosine as another drug worth 
looking at. The attempt to translate the marked 
experimental schedule dependency for arabanosyl 
cytosine to the clinical situauon of acute myelo-
cytic leukemia has led to a myriad of schedules 
being attempted. These are outlined in Figure 15 
(1:3 17) . As shown in Figure 15. acti,·ity has been 
found un a wide range of schedules. some of 
\\hich have little correlation with the schedule 
dependency seen in Ll:HO. Is there a satisfactol) 
explanation for the apparent lack of correlation 
between animal and human data in terms of 
schedule dependency? Additional studies in the 
Ll210 leukemia system reveal that the schedule 
dependency involving "around the clock" lherap) 
every 4 days, so marked in the treatment of early 
leukemia Ll ~1 0, is not evident for advanced dis-
ease (Figure 16). Precise correspondence uf mo-
Compan,on of Ara-C Srhedule in the treatm(•nt of early and adL•anced leukemia L/2/0 
One injection/day 
Daily 
Every 2 day~ 
Eve~ 4 dayb 
Every 8 dayh 
Eight injections/day IQ3H/day) 
Daily 
E"ery 2 days 
Every -t days 
Every H day~ 
to• Ll210 a'ciaes i.p. 
f',.,.rh lt ·ukt-nua IP trtoal m t·nt 
d.tth I !I 
OJ1t1mdl tin•• 













222 ( :1) 
> 422 (I) 
111 
Data of I. Kline. PI a/., Microbiologwol Associates. 
FIG. 16 
..\d\anr.:td l tukt·m~• IJ> t N·i\tmrnl 
d.t\t ~ II 
Oprirrutl d • ._ 


















Til F. .JOl R\o \I OF 1\o\ ~STIGATI\ F. DERMA rOLOC;' 
dolitie,.. ul rhemntht>rap~ in animal ,..y:-.tem!. and 
thl' clinil· must surely require cll'tnill'd una)y,..j, of 
tnctor:-.. !.Uch a:- ~~a~t: nl di~ease. influenl'inJ! 
schedule clcpl'nrll'nQ'. Thi,.. in turn muy pl'rmit 
mnn• apprnprhll!• w-siJ.rnment ut dntf.! :-chl'dulim: 
in <H't·nrdanrc wu h pat it•nt ,..l:lllh. . 
The impurtanre o l rhnracterization ot drugs 
with respel'l to srh£>dul1• depl'nd!•rw~· characteris-
tics ha,.. been dl•urly recogn11.ed. and in the 
l'h£>motherapy ProJ!ram of the '\CI all uf th<> 
knm\n und potl•ntially usetul antitumor agt•nb 
are lwing -.tudii'CI in nrdt•r to dl'terminc uptirnal 
"rhl'dulinJ! in tht·rapy. 
In cnnclusinn, thr seanh lor thrrupeutil' l'ontrul 
ol neopla~t il· t•elb as ptorformed by the Cherno· 
therap~ Program is ha!wcl on l't•rlnin u,..sumptions. 
These ossumpt ion-. a.s dul'id,rtccl by Zubrod Ill 
arc outlmed helm\ : 
I 'l'w drug,.. with po,..siblt: antitumor clll'l't i\ e· 
n<'l's ... hould ht• sought both t•mpirically and 
rationally I rom the w id£>sl possihll' bn:sc 
nmong -..yntht•lit· rhemirrlls and naturill 
pmdut·t,.., 
:.!. Drugs can lw ll>und with -.utfit'ient l·aparity 
to kill tumnr t' l'll,.. and prnclun· permarwnt 
rnrnplcte rcmr,..sion within tht• limits ot Uc· 
r£>ptahle mnrhrdll\ to thE:' pntumt . 
:1 Hoth tumor n•ll kill t•apari t" unci tuxit' ct-
lt:t'l,.. ol dnsgs m patient:s ran lw predil·ted 
trum dru~: clh'ds in animal model,.., 
1. Animal modds hast'd un wmur·t·t•ll kim•tir-. 
t'Un predkt druJ: clll'C.'h in pat it•nt~ with n 
hi~her t>robability ul ... ut'l'ess than is possihll• 
in nunkinet it• mod£>!.... 
;i, DruJ: ellel't:- 1n uiru t•an he acll'<JUOtely a~ · 
-.c,..scd only \\hen the exposurl• tim£> of t·clls 
to -.pet'ilk anwunh nl drug,.. l'Un hl' c:stah-
li:-.ht>d. 
6. Anrmal moclt•ls that have precllt•ted knm\n 
!•lferu"e dm.:,.. "ill prcdit·t Ill'\\ ellel't iH• 
drug,.. , addllwnal unrmol models wtll also lw 
m·edcd. 
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II S!!lilwr' 0 " Honnni.m . . 1 .. \\'nlmnn, I. ,J , Ahir. 
F ( IU'\'Rht·r l. C~uurdenu. H., O.·nt•m R 
c;u,sttll, H. 1> .. l.t·\·\ , H .. Bur~:<:rt . 0 .. :\! ilk ~ . 
D . Hlum, .1, .Jnnl',..," H .• Pnttt•r,un, R R. \lcln 
ryr<' 0 H , Hauram. ~· . 1.. \I non . . 1. H Hnnj!· 
,tr.llt•n. IL Kung, F. H .. ShN·ht>. 1'. H .. !-rei. £ . 
and fluJinnd, ,J r.: ;-,:('\\ lrl'Olllll'lll ~~ ht•duJe 
\\ i th m(Jrct\l•d ~unr\ ,tl in chilclhcwlCI lt•ukt·mia 
.J A.:\1 A., 191· 75. ltlt.{J, 
t·• Livin~"tnn , H. B. and Curfl!r. ~. 1\ -"rn~:lt • : \ 1/•·n/;, 
in Cancrr Chemuthrrap) l'l~nu n: Prl.'•~. ::-\c\' 
\'nrk, 1!1711 
t:l. Bud!'\. <: P Fretrt•idl, E .• 1 .. :\luntn, H. \\ .md 
llr \\lt•tt , .) S . C\tnsin<' .\ralunnsidl· t'\'S(' 
6:lh71'il rhtrup~ lnr .Kull• lt:ukt!mia in uduh"' Can 
n·r ( 'ht·mntht•r. Rqt., .';;l. 1i9. J!)H9. 
t l. Cnrt·y, H \\'.: comtlJir.tlln• stuclv f•l n ·ro-tnc <1m· 
hin• ~:> 11h· tht·rnp~ alum• and cct~nhirwd " ith thio. 
guanint'. m••n·npt~>purint· ur clunnumy•·in . l'rc~e. 
;\mt•r. ,, ,,..,,. l'ann•r Ht•,. .. II. Iii. 1!17!1. 
t fl. 1-:Jii,on, R H.. Hnlland . . J. H., \\'eil. :\.1 .. . Jat·4uillat. 
C .. H<•irnn, :\1.. Bt·rnttrd . . 1. S il\\ill-k\', A .. Hc,..ner. 
F .. c;u,,..nlt , H .. SiiH'r, It T .. 1\arann,, ,\ . Cutt · 
nt•r, .}., Spurr ( I ., Hun'S, [) :\l , Hlom, .1.. 
Lf'ltnt•, L. ,\ ., Haurnm. H. K .. Hutchin~un. ,J. L .. 
FnrdN. H. ,J. and .\1c><Jtl , .1. 11.: Ar.thinu'' I C\lt t-
,.im•: ,\ usl.'lul H!(ent tn tht• tn•at m<·nt ut n<:utt• ll'u· 
kt•mia 111 ndult-.. . HlcHwl , :1:!: ;,o7. Hill!'. 
11; l:uuclt' ll, B. and Ht•ndt·N•n. r:. l!H• nl ntu,ine 
arahinc~idt• in arull• mHI<IC\'t k lcukt•rni~. C'hn. 
l'harmllt~•l I hl'r In ptt·:.... · 
17 Hl.'ndl'r~un , r: S. atHI Burkt•, 1' . . }.: C'liruntl l'~J)('T· 
wnn· "irh Cvtu-int: ,\rahinu, idt: Pnt~·. -\mer 
, \,.. ... cl(' , ('unn·r ~,. .. ti Hl!!. l lw . 
